Metabolic Reprogramming of Liver Fibrosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is an excessive and imbalanced deposition of fibrous extracellular matrix (ECM) that is associated with the hepatic wound-healing response. It is also the common mechanism that contributes to the impairment of the liver function that is observed in many chronic liver diseases (CLD). Despite the efforts, no effective therapy against fibrosis exists yet. Worryingly, due to the growing obesity pandemic, fibrosis incidence is on the rise. Here, we aim to summarize the main components and mechanisms involved in the progression of liver fibrosis, with special focus on the metabolic regulation of key effectors of fibrogenesis, hepatic stellate cells (HSCs), and their role in the disease progression. Hepatic cells that undergo metabolic reprogramming require a tightly controlled, fine-tuned cellular response, allowing them to meet their energetic demands without affecting cellular integrity. Here, we aim to discuss the role of ribonucleic acid (RNA)-binding proteins (RBPs), whose dynamic nature being context- and stimuli-dependent make them very suitable for the fibrotic situation. Thus, we will not only summarize the up-to-date literature on the metabolic regulation of HSCs in liver fibrosis, but also on the RBP-dependent post-transcriptional regulation of this metabolic switch that results in such important consequences for the progression of fibrosis and CLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011 · cited 1×
“At later stages of fibrosis, the basement membrane also increases its mass and rigidity due to the gain in collagen deposition which varies depending on the type and degree of injury, while at the same time, gives rise to the characteristic periportal fibrosis [39,42].”
BackgroundHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“They are the primary fibrogenic cell type in the injured liver, accounting for most of the MFBs that are involved in the process of hepatic fibrosis [50].”
BackgroundInflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · cited 1×
“Indeed, recent publications highlight the role of RNAs as important regulators of stress responses and metabolic disruptions [119,120].”
BackgroundSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 10×
“Finally, the activated HSCs proceed to their own secretion of proinflammatory mediators (TGFβ, C-X-C motif chemokine Ligand 12/CXCL12, monocyte chemoattractant protein 1/MCP1, IL-10, and IL-8) and adhesion molecules (vascular cell adhesion molecule 1/VCAM-1) that help with the recruiting of more inflammatory cells, pe…”
BackgroundInfluentialGlobal epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443 · cited 1×
“Several studies using different labelling methods suggest that, in the case of hepatotoxic injury, HSCs represent more than 80% of the MFBs that are present in the damaged liver [33,34].”
BackgroundLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757 · cited 1×
“Hepatic fibrosis also generates a permissive micro-environment for the development of tumorigenic nodules through mechanisms that are still under debate [6], but nevertheless, increasing the risk for cancer [7].”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 8×
“In this regard, KC-derived IL-1 was shown to potently downregulate the mRNA and protein levels of LRAT without affecting the protein stability, thereby favoring the mobilization of RE as well as the activation of primary HSCs [106].”
BackgroundInfluentialHernández–Gea, V., Ghiassi–Nejad, Z., Rozenfeld, R., Gordon, R., Fiel, M. I., Yue, Z., Czaja, M. J., & Friedman, S. L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.044 · Cited by 654
Pradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 3×
“Abbreviations Acetyl-CoA carboxylase: ACC; Adenosine triphosphate: ATP; Adenylate-uridylate (AU)-rich elements: AREs; Adipose triglyceride lipase: ATGL Arginase 1: ARG1; AU-rich element-binding proteins: AUBPs; Autophagy-related 16-like 1: ATG16L1; B-cell lymphoma 2: BCL2; C-C chemokine receptor type 2: CCR2 C-X-C Mot…”
BackgroundVitamin A metabolism: An update
D’Ambrosio, D. N., Clugston, R. D., & Blaner, W. S. (2011) · Nutrients · doi:10.3390/nu3010063 · Cited by 562 · cited 1×
“In normal conditions, retinol from the diet is esterified, transported, and hydrolyzed in hepatocytes [56,57].”
BackgroundOrigin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535 · cited 3×
“Thus, the exact source and contribution to the MFBs pool might highly depend on the evolution and type of injury [5,34].”
BackgroundThe Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420 · cited 3×
“These results suggest that the patterns of HSC activation overlap with the areas of injury while at the same time it opens a possibility to develop new strategies to target only the pathogenic collagen-producing cell population, with the minimum perturbation of the liver function [69].”
BackgroundClinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411 · cited 1×
“However, even clinical cirrhosis is considered a reversible process [21,22].”
BackgroundXie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410
DeLeve, L. D., Wang, X., & Guo, Y. (2008) · Hepatology · doi:10.1002/hep.22351 · Cited by 408 · cited 1×
“In a healthy liver, LSECs help to maintain the quiescent phenotype of HSCs by the secretion of paracrine factors, for instance nitric oxide (NO) among others [5,72,73].”
BackgroundMAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401 · cited 1×
“This new condition is defined as a cluster of fatty liver diseases that are associated with metabolic dysfunction [15] and it is considered a better criteria to identify patients with significant fibrosis via noninvasive methods [16].”
BackgroundThe role of TGFβ1 in initiating hepatic stellate cell activation in vivo
Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80010-5 · Cited by 393
Hepatic stellate cells require a stiff environment for myofibroblastic differentiation
Olsen, A. L., Bloomer, S. A., Chan, E. P., Gaça, M. D. A., Georges, P. C., Sackey, B., Uemura, M., Janmey, P. A., & Wells, R. G. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2010 · Cited by 355
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
Correia, A. L., Guimaraes, J. C., Auf der Maur, P., De Silva, D., Trefny, M. P., Okamoto, R., Bruno, S., Schmidt, A., Mertz, K., Volkmann, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03614-z · Cited by 339
Ibrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278 · cited 1×
“However, due to the growing obesity epidemic, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are considered the major precursors of fibrosis and liver failure nowadays [13,14].”
BackgroundLeroux, A., Ferrere, G., Godie, V., Cailleux, F., Renoud, M.-L., Gaudin, F., Naveau, S., Prévot, S., Makhzami, S., Perlemuter, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.028 · Cited by 246
Schnabl, B., Purbeck, C. A., Choi, Y. H., Hagedorn, C. H., & Brenner, D. (2003) · Hepatology · doi:10.1053/jhep.2003.50097 · Cited by 224 · cited 1×
“But they also help in the resolution of fibrosis as they diminish the secretion and expression of ECM proteins [5,83,86,87].”
BackgroundHepatic metabolism of retinoids and disease associations
Shirakami, Y., Lee, S.-A., Clugston, R. D., & Blaner, W. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.06.023 · Cited by 203 · cited 1×
“In normal conditions, retinol from the diet is esterified, transported, and hydrolyzed in hepatocytes [56,57].”
BackgroundTissue inhibitors of metalloproteinases in liver fibrosis
Iredale, J. P. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00118-5 · Cited by 165
Heterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Beaven, S. W., Wroblewski, K., Wang, J., Hong, C., Bensinger, S., Tsukamoto, H., & Tontonoz, P. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.053 · Cited by 131
Transcriptional regulation of Hepatic Stellate Cell activation in NASH
Marcher, A.-B., Bendixen, S. M., Terkelsen, M. K., Hohmann, S. S., Hansen, M. H., Larsen, B. D., Mandrup, S., Dimke, H., Detlefsen, S., & Ravnskjaer, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-39112-6 · Cited by 95 · cited 1×
“In this regard, while the transcriptional networks that regulate fibrogenesis and HSCs transdifferentiation are extensively studied ([9,115,116] among others), how RNA regulatory processes control the metabolic rewiring of fibrogenesis remains less understood [117].”
BackgroundMetabolic reprogramming in tumors: Contributions of the tumor microenvironment
Lane, A. N., Higashi, R. M., & Fan, T. W.-M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.007 · Cited by 91
Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver
Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316137 · Cited by 91
Kietzmann, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092347 · Cited by 90
Maillo, C., Martín, J., Sebastián, D., Hernández-Alvarez, M., García-Rocha, M., Reina, O., Zorzano, A., Fernandez, M., & Méndez, R. (2017) · Nature Cell Biology · doi:10.1038/ncb3461 · Cited by 82
Targeting cell-intrinsic metabolism for antifibrotic therapy
Gilgenkrantz, H., Mallat, A., Moreau, R., & Lotersztajn, S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.012 · Cited by 76 · cited 3×
“the better understanding of these regulatory processes affecting this metabolic switch have opened new opportunities for therapeutic intervention in the recent years [97,116].”
BackgroundHepatic fibrosis: A convergent response to liver injury that is reversible
Wang, S., & Friedman, S. L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.011 · Cited by 62 · cited 1×
“Hepatic fibrosis also generates a permissive micro-environment for the development of tumorigenic nodules through mechanisms that are still under debate [6], but nevertheless, increasing the risk for cancer [7].”
Background
Cited by
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“Recent studies revealed that cells involved in the development and regression of liver fibrosis undergo metabolic reprogramming to meet their energy requirements [141–143].”
BackgroundInsights on drug and gene delivery systems in liver fibrosis
Vyas, K., & Patel, M. M. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100779 · Cited by 30
Huang, T., Zhou, M.-Y., Zou, G.-L., Hu, R.-H., Han, L., Zhang, Q.-X., & Zhao, X.-K. (2025) · Scientific Reports · doi:10.1038/s41598-025-88538-8 · Cited by 14
(2024) · doi:10.21203/rs.3.rs-5072199/v1 · Cited by 14
Metadata
- Authors
- Delgado, M. E., Cárdenas, B. I., Farran, N., & Fernandez, M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-12-20
- Volume
- 10
- Issue
- 12
- Pages
- 3604
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4200238838
- Cited by
- 71
- References
- 44
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.